https://www.cancernetwork.com/view/52-theres-no-place-like-home-best-practices-bringing-cutting-edge-breast-cancer-treatments-closer-to-home2026-06-22T22:00:00Z2026-06-22T22:00:00Z https://www.cancernetwork.com/view/fda-approves-afami-cel-in-metastatic-synovial-sarcoma2026-06-22T20:18:58.039Z2026-06-22T20:18:58.039Z https://www.cancernetwork.com/view/tropion-breast01-and-comparative-adc-data2026-06-22T20:17:02.345Z2026-06-22T20:17:02.345Z https://www.cancernetwork.com/view/introduction-and-treatment-landscape-overview2026-06-22T20:10:15.798Z2026-06-22T20:10:15.798Z https://www.cancernetwork.com/view/how-are-key-lymphoma-data-from-asco-and-eha-2026-shaping-treatment2026-06-22T20:00:00Z2026-06-22T20:00:00Z https://www.cancernetwork.com/view/exploring-the-future-of-bladder-sparing-regimens-in-the-mibc-landscape2026-06-22T19:00:00Z2026-06-22T19:00:00Z https://www.cancernetwork.com/view/binimetinib-tablets-receive-tentative-fda-approval-in-melanoma-nsclc2026-06-22T17:00:00Z2026-06-22T17:00:00Z https://www.cancernetwork.com/view/the-moonlight-shift-dr-joshua-richter-on-myeloma-myths-and-the-c-word2026-06-22T16:00:00Z2026-06-22T16:00:00Z https://www.cancernetwork.com/view/ec-approves-encorafenib-cetuximab-folfox-in-1l-braf-v600e-mutant-mcrc2026-06-22T14:45:24.211Z2026-06-22T14:45:24.211Z https://www.cancernetwork.com/view/obesity-and-cancer-risk-the-evolving-role-of-glp-1s-in-oncology2026-06-22T14:00:00Z2026-06-22T14:00:00Z https://www.cancernetwork.com/view/checkpoint-inhibitor-evidence-empower-and-c-post-trials2026-06-22T12:05:00Z2026-06-22T12:05:00Z https://www.cancernetwork.com/view/daratumumab-based-frontline-therapy-in-newly-diagnosed-multiple-myeloma2026-06-22T12:05:00Z2026-06-22T12:05:00Z https://www.cancernetwork.com/view/exploring-the-future-of-artificial-intelligence-and-thoracic-oncology2026-06-22T12:00:00Z2026-06-22T12:00:00Z https://www.cancernetwork.com/view/when-to-consider-systemic-therapy-for-cscc2026-06-22T12:00:00Z2026-06-22T12:00:00Z https://www.cancernetwork.com/view/evolving-frontline-management-in-newly-diagnosed-multiple-myeloma2026-06-22T12:00:00Z2026-06-22T12:00:00Z https://www.cancernetwork.com/view/53-us-patient-perspectives-on-capivasertib-plus-fulvestrant-dosing-tolerability-and-blood-glucose-monitoring-from-qualitative-interviews2026-06-21T22:30:00Z2026-06-21T22:30:00Z https://www.cancernetwork.com/view/54-pleomorphic-invasive-lobular-carcinoma-multimodality-imaging-findings-in-cases-from-the-university-of-rochester-medical-center2026-06-21T22:00:00Z2026-06-21T22:00:00Z https://www.cancernetwork.com/view/3-things-you-should-know-about-frontline-and-maintenance-therapy-for-her2-metastatic-breast-cancer2026-06-21T18:00:00Z2026-06-21T18:00:00Z https://www.cancernetwork.com/view/how-do-you-choose-the-right-frontline-therapy-in-cll-care-2026-06-21T16:00:00Z2026-06-21T16:00:00Z https://www.cancernetwork.com/view/55-intramammary-spindle-cell-lesions-imaging-pathology-correlation2026-06-20T22:30:00Z2026-06-20T22:30:00Z https://www.cancernetwork.com/view/56-prospective-study-of-quantitative-near-infrared-spectroscopy-for-noninvasive-assessment-of-suspicious-breast-lesions2026-06-20T22:00:00Z2026-06-20T22:00:00Z https://www.cancernetwork.com/view/3-things-you-should-know-about-using-selective-estrogen-receptor-degraders-in-hormone-receptor-positive-her2-negative-advanced-breast-cancer2026-06-20T18:00:00Z2026-06-20T18:00:00Z https://www.cancernetwork.com/view/57-altered-biomechanics-drives-outcome-in-breast-cancer-a-new-avenue-for-oncology-biomarkers2026-06-19T22:30:00Z2026-06-19T22:30:00Z https://www.cancernetwork.com/view/58-an-evidence-based-self-management-planner-for-patients-with-metastatic-triple-negative-breast-cancer-a-multi-channel-dissemination-initiative2026-06-19T22:00:00Z2026-06-19T22:00:00Z https://www.cancernetwork.com/view/trident-trial-finds-no-survival-benefit-with-earlier-tumor-treating-fields-use2026-06-19T20:00:00Z2026-06-19T20:00:00Z https://www.cancernetwork.com/view/fda-accepts-sc-mosunetuzumab-combo-sbla-in-relapsed-refractory-lbcl2026-06-19T17:00:00Z2026-06-19T17:00:00Z https://www.cancernetwork.com/view/asco-2026-key-insights-in-renal-cell-carcinoma-merkel-cell-carcinoma-and-chronic-myeloid-leukemia2026-06-19T16:00:00Z2026-06-19T16:00:00Z https://www.cancernetwork.com/view/3-things-you-should-know-about-cutaneous-squamous-cell-carcinoma2026-06-19T14:00:00Z2026-06-19T14:00:00Z https://www.cancernetwork.com/view/59-racialized-economic-segregation-and-insurance-disadvantage-as-mediators-of-racial-disparities-in-breast-cancer-stage-at-diagnosis2026-06-18T22:30:00Z2026-06-18T22:30:00Z https://www.cancernetwork.com/view/60-racialized-economic-segregation-as-a-mediator-of-racial-disparities-in-triple-negative-breast-cancer2026-06-18T22:00:00Z2026-06-18T22:00:00Z https://www.cancernetwork.com/view/evaluating-bladder-sparing-strategies-and-key-gu-data-from-asco-20262026-06-18T20:00:00Z2026-06-18T20:00:00Z https://www.cancernetwork.com/view/emerging-t-cell-engagers-and-novel-immunotargets-in-multiple-myeloma2026-06-18T18:00:00Z2026-06-18T18:00:00Z https://www.cancernetwork.com/view/first-line-maintenance-ibrutinib-improves-survival-in-tp53-mutated-mcl2026-06-18T17:00:00Z2026-06-18T17:00:00Z https://www.cancernetwork.com/view/nccn-expands-csf-molecular-profiling-recommendation-to-inoperable-high-grade-glioma2026-06-18T16:00:11.485Z2026-06-18T16:00:11.485Z https://www.cancernetwork.com/view/revolutionizing-oncology-in-the-digital-age-effects-on-health-care-providers2026-06-18T14:00:00Z2026-06-18T14:00:00Z https://www.cancernetwork.com/view/61-economic-burden-of-neutropenia-among-patients-treated-for-hr-her2-and-triple-negative-metastatic-breast-cancer-in-the-united-states-a-retrospective-claims-analysis2026-06-17T22:30:00Z2026-06-17T22:30:00Z https://www.cancernetwork.com/view/62-integrating-dose-modifications-for-effective-management-of-hr-her2-early-breast-cancer-with-abemaciclib2026-06-17T22:00:00Z2026-06-17T22:00:00Z https://www.cancernetwork.com/view/givastomig-earns-fda-fast-track-designation-in-her2-negative-gastric-cancer2026-06-17T17:00:14.192Z2026-06-17T17:00:14.192Z https://www.cancernetwork.com/view/from-conference-to-practice-top-5-takeaways-from-eha-20262026-06-17T16:00:00Z2026-06-17T16:00:00Z https://www.cancernetwork.com/view/managing-toxicities-associated-with-adcs-in-metastatic-tnbc2026-06-17T14:00:00Z2026-06-17T14:00:00Z https://www.cancernetwork.com/view/historical-evolution-and-current-treatment-landscape2026-06-17T12:00:00Z2026-06-17T12:00:00Z https://www.cancernetwork.com/view/63-patient-and-provider-related-diagnostic-delay-in-pregnancy-associated-breast-cancer-a-descriptive-systematic-review2026-06-16T22:30:00Z2026-06-16T22:30:00Z https://www.cancernetwork.com/view/64-a-phase-i-ii-study-of-pembrolizumab-and-anti-cd3-x-anti-her2-armed-activated-t-cells-in-metastatic-breast-cancer2026-06-16T22:00:00Z2026-06-16T22:00:00Z https://www.cancernetwork.com/view/analyzing-adc-options-across-metastatic-tnbc2026-06-16T20:00:00Z2026-06-16T20:00:00Z https://www.cancernetwork.com/view/pembrolizumab-combo-shows-efficacy-in-pediatric-high-risk-hodgkin-lymphoma2026-06-16T17:00:00Z2026-06-16T17:00:00Z https://www.cancernetwork.com/view/eli-002-7p-misses-primary-end-point-phase-2-amplify-7p-pdac-study2026-06-16T16:30:00Z2026-06-16T16:30:00Z https://www.cancernetwork.com/view/cd47-antibody-combo-shows-meaningful-activity-in-previously-untreated-aml2026-06-16T16:00:00Z2026-06-16T16:00:00Z https://www.cancernetwork.com/view/fda-accepts-bla-for-ozekibart-in-unresectable-or-metastatic-chondrosarcoma2026-06-16T15:00:00Z2026-06-16T15:00:00Z https://www.cancernetwork.com/view/elucidating-first-line-sc-mosunetuzumab-benefit-in-follicular-lymphoma2026-06-16T12:00:00Z2026-06-16T12:00:00Z https://www.cancernetwork.com/view/tip65-the-impact-of-aromatase-inhibitor-use-on-cardiorespiratory-fitness-in-post-menopausal-breast-cancer-patients2026-06-15T22:30:00Z2026-06-15T22:30:00Z https://www.cancernetwork.com/view/tip66-feasibility-of-the-thrive-wellness-program-for-young-breast-cancer-survivors-a-multicenter-pilot-trial2026-06-15T22:00:00Z2026-06-15T22:00:00Z https://www.cancernetwork.com/view/belantamab-mafodotin-regimen-yields-enduring-responses-in-ndmm2026-06-15T20:29:14.915Z2026-06-15T20:29:14.915Z https://www.cancernetwork.com/view/fda-approves-gadoquatrane-detect-cns-body-region-lesions2026-06-15T20:00:05.724Z2026-06-15T20:00:05.724Z https://www.cancernetwork.com/view/brentuximab-vedotin-chemo-regimens-show-similar-efficacy-in-2l-lymphoma2026-06-15T19:00:00Z2026-06-15T19:00:00Z https://www.cancernetwork.com/view/fda-clears-alpha-dart-trial-complete-enrollment-recurrent-gbm2026-06-15T15:58:40.268Z2026-06-15T15:58:40.268Z https://www.cancernetwork.com/view/arlo-cel-produces-deep-responses-in-pretreated-r-r-multiple-myeloma2026-06-15T14:31:12.341Z2026-06-15T14:31:12.341Z https://www.cancernetwork.com/view/multidisciplinary-referral-for-patients-with-cscc-and-care-transitions2026-06-15T12:01:00Z2026-06-15T12:01:00Z https://www.cancernetwork.com/view/introduction-and-current-landscape-of-cutaneous-squamous-cell-carcinoma2026-06-15T12:00:00Z2026-06-15T12:00:00Z https://www.cancernetwork.com/view/navigating-personality-disorders-in-cancer-care2026-06-15T12:00:00Z2026-06-15T12:00:00Z https://www.cancernetwork.com/view/67-spirituality-and-medical-trust-among-breast-cancer-outpatients-in-an-urban-safety-net-setting2026-06-14T22:30:00Z2026-06-14T22:30:00Z https://www.cancernetwork.com/view/68-breast-cancer-stem-cells-and-genomic-drivers-of-therapeutic-resistance2026-06-14T22:00:00Z2026-06-14T22:00:00Z https://www.cancernetwork.com/view/sonrotoclax-plus-zanubrutinib-achieves-90-umrd-in-treatment-naive-cll-sll2026-06-14T21:00:00Z2026-06-14T21:00:00Z 90% uMRD in Treatment-Naive CLL/SLL]]> https://www.cancernetwork.com/view/sc-mosunetuzumab-exhibits-response-durability-in-follicular-lymphoma2026-06-14T20:00:00Z2026-06-14T20:00:00Z https://www.cancernetwork.com/view/pirtobrutinib-plus-venetoclax-rituximab-improves-pfs-in-pretreated-cll2026-06-14T19:00:00Z2026-06-14T19:00:00Z https://www.cancernetwork.com/view/pirtobrutinib-regimen-may-offer-prolonged-remissions-in-pretreated-cll2026-06-14T18:00:00Z2026-06-14T18:00:00Z https://www.cancernetwork.com/view/ziftomenib-7-3-high-response-rates-newly-diagnosed-aml2026-06-14T17:30:00Z2026-06-14T17:30:00Z https://www.cancernetwork.com/view/liso-cel-demonstrates-real-world-efficacy-in-relapsed-refractory-mcl2026-06-14T17:00:00Z2026-06-14T17:00:00Z https://www.cancernetwork.com/view/favezelimab-combo-boosts-pfs-vs-chemo-in-pd-1-refractory-hodgkin-lymphoma2026-06-14T15:30:00Z2026-06-14T15:30:00Z https://www.cancernetwork.com/view/69-assessing-the-impact-and-efficacy-of-anthracyclines-and-trastuzumab-alternatives-on-potential-cardiotoxicity-in-breast-cancer-patients2026-06-13T22:30:00Z2026-06-13T22:30:00Z https://www.cancernetwork.com/view/70-real-world-outcomes-and-toxicity-of-trastuzumab-deruxtecan-in-older-adults-with-breast-cancer-a-mayo-clinic-multi-site-analysis2026-06-13T22:00:00Z2026-06-13T22:00:00Z https://www.cancernetwork.com/view/brecadd-improves-pfs-vs-nivolumab-avd-in-advanced-stage-hodgkin-lymphoma2026-06-13T21:30:00Z2026-06-13T21:30:00Z https://www.cancernetwork.com/view/cd20-cd3-bispecific-antibodies-may-be-feasible-bridging-strategy-in-lbcl2026-06-13T19:00:00Z2026-06-13T19:00:00Z https://www.cancernetwork.com/view/blinatumomab-substitution-improves-efs-in-pediatric-high-risk-b-all2026-06-13T18:00:00Z2026-06-13T18:00:00Z https://www.cancernetwork.com/view/epcoritamab-yields-superior-pfs-vs-chemoimmunotherapy-in-pretreated-lbcl2026-06-13T16:15:00Z2026-06-13T16:15:00Z https://www.cancernetwork.com/view/talquetamab-daratumumab-improves-pfs-in-relapsed-refractory-myeloma2026-06-13T15:30:00Z2026-06-13T15:30:00Z https://www.cancernetwork.com/view/71-timing-of-neoadjuvant-immunotherapy-and-pathological-response-in-early-stage-triple-negative-breast-cancer-a-literature-review-and-case-series2026-06-12T22:30:00Z2026-06-12T22:30:00Z https://www.cancernetwork.com/view/72-clonal-hematopoiesis-and-anthracycline-cardiotoxicity-in-breast-cancer-a-missed-opportunity-in-cardio-oncology-risk-stratification-2026-06-12T22:00:00Z2026-06-12T22:00:00Z https://www.cancernetwork.com/view/luspatercept-elicits-enduring-benefit-in-lower-risk-mds-population2026-06-12T21:00:00Z2026-06-12T21:00:00Z https://www.cancernetwork.com/view/quadruplet-combo-appears-effective-in-high-risk-smoldering-multiple-myeloma2026-06-12T19:46:35.110Z2026-06-12T19:46:35.110Z https://www.cancernetwork.com/view/polatuzumab-rituximab-display-tolerability-in-frail-older-dlbcl-groups2026-06-12T19:15:00Z2026-06-12T19:15:00Z https://www.cancernetwork.com/view/capivasertib-combo-earns-fda-approval-in-pten-deficient-metastatic-hspc2026-06-12T18:36:19.397Z2026-06-12T18:36:19.397Z https://www.cancernetwork.com/view/fda-approves-adjuvant-belzutifan-pembrolizumab-in-clear-cell-rcc-post-nephrectomy2026-06-12T16:47:05.723Z2026-06-12T16:47:05.723Z https://www.cancernetwork.com/view/lurbinectedin-misses-survival-end-point-in-second-line-sclc-trial2026-06-12T15:00:00Z2026-06-12T15:00:00Z https://www.cancernetwork.com/view/atezolizumab-chemo-earns-fda-priority-review-in-stage-iii-dmmr-msi-h-colon-cancer2026-06-12T14:30:00Z2026-06-12T14:30:00Z https://www.cancernetwork.com/view/azacitidine-triplet-produces-durable-mrd-negative-remissions-in-idh1-aml2026-06-12T14:00:00Z2026-06-12T14:00:00Z https://www.cancernetwork.com/view/how-does-asciminib-compare-with-other-tkis-in-long-term-cml-cp-care-2026-06-12T13:00:00Z2026-06-12T13:00:00Z https://www.cancernetwork.com/view/73-the-adc-era-in-breast-cancer-contemporary-sequencing-strategies-and-evidence-based-toxicity-management2026-06-11T22:30:00Z2026-06-11T22:30:00Z https://www.cancernetwork.com/view/74-real-world-study-characterizing-patient-characteristics-treatments-and-unmet-need-in-io-ineligible-patients-with-metastatic-triple-negative-breast-cancer2026-06-11T22:00:00Z2026-06-11T22:00:00Z https://www.cancernetwork.com/view/fixed-duration-epcoritamab-combo-shows-superiority-in-follicular-lymphoma2026-06-11T20:30:00Z2026-06-11T20:30:00Z https://www.cancernetwork.com/view/tisa-cel-yields-enduring-remissions-in-younger-high-risk-b-all-population2026-06-11T18:30:00Z2026-06-11T18:30:00Z https://www.cancernetwork.com/view/vt-ebv-n-yields-durable-disease-free-survival-in-pretreated-enktl2026-06-11T18:00:00Z2026-06-11T18:00:00Z https://www.cancernetwork.com/view/anbenitamab-regimen-meets-phase-3-end-points-in-her2-breast-cancer2026-06-11T16:56:31.804Z2026-06-11T16:56:31.804Z https://www.cancernetwork.com/view/asco-2026-translating-the-top-prostate-cancer-data-into-clinical-action2026-06-11T12:00:00Z2026-06-11T12:00:00Z https://www.cancernetwork.com/view/75-trastuzumab-deruxtecan-her2-low-metastatic-breast-cancer-real-world-treatment-patterns-outcomes-community-oncology-settings2026-06-10T22:30:00Z2026-06-10T22:30:00Z https://www.cancernetwork.com/view/76-real-world-safety-trastuzumab-deruxtecan-her2-low-metastatic-breast-cancer-insights-us-community-oncology-practices2026-06-10T22:00:00Z2026-06-10T22:00:00Z https://www.cancernetwork.com/view/asciminib-may-offer-longer-better-life-in-frontline-cml-care2026-06-10T19:00:00Z2026-06-10T19:00:00Z https://www.cancernetwork.com/view/investigators-halt-phase-3-trial-of-sacituzumab-govitecan-combo-in-nsclc2026-06-10T14:30:00Z2026-06-10T14:30:00Z https://www.cancernetwork.com/view/rethinking-academic-support-sustainability-for-clinical-cancer-research2026-06-10T12:00:00Z2026-06-10T12:00:00Z https://www.cancernetwork.com/view/77-updated-efficacy-mutant-selective-pi3kalpha-inhibitor-zovegalisib-rly-2608-combination-fulvestrant-pik3ca-mutant-hr-her2-advanced-breast-cancer-rediscover-trial2026-06-09T22:30:00Z2026-06-09T22:30:00Z https://www.cancernetwork.com/view/78-liquid-biopsy-insights-genomic-drivers-of-endocrine-resistance-in-breast-cancer2026-06-09T22:00:00Z2026-06-09T22:00:00Z